Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis

Authors:

Abstract
No abstract available
Funding Information
  • Centers for Disease Control and Prevention (75D30121D12779)
  • Centers for Disease Control and Prevention (75D30123C18039)

This publication has 38 references indexed in Scilit: